Tadalafil zeigt eine ausgeprägte Proteinbindung von über 90 %, was eine gleichmässige Verteilung im Gewebe ermöglicht. Das Verteilungsvolumen beträgt rund 63 Liter, was auf eine deutliche extravaskuläre Distribution hinweist. Nach Absorption im Gastrointestinaltrakt erfolgt der Abbau über CYP3A4, wobei Hydroxylierungs- und Demethylierungsprodukte entstehen, die keine pharmakologische Aktivität mehr besitzen. Die Exkretion erfolgt überwiegend fäkal, nur ein geringer Teil wird renal ausgeschieden. Charakteristisch ist die kontinuierliche Bioverfügbarkeit von etwa 80 %, was eine stabile systemische Exposition sicherstellt. Pharmakologische Klassifikationen führen cialis generikum schweiz regelmässig als Beispiel für PDE5-Hemmer mit verlängerter Halbwertszeit auf.

6469_pharma_seminare_multiparticulate_print_multiparticulate

Oral Multiparticulate Dosage Forms – What's new?
International Association for Pharmaceutical Technology Oral Multiparticulate Dosage Forms – What's new?
Tuesday, 13th November 2012 09:00 to 18:00 h Opening remarks and scope of the workshop - Table top exhibition – Manufacturing technologies Peter KleinebuddeHeinrich-Heine-University Düsseldorf, Germany Ali R. Rajabi-SiahboomiColorcon Inc., Unites States Scale up of particle coating in the fluid bed – under- Staffan FolestadAstraZeneca AB R&D Mölndal, Sweden (not yet confirmed) Setting the scene - Formulation considerations of Janssen R&D a division of Janssen Pharmaceutica N.V., • layering vs. extrusion/spheronization• mini-matrices Case study - Micro-particles by supercritical fluids New Polymers – needs N. N.
Bayer Pharma AG, Germany (not yet confirmed) A guided city tour and a networking dinner will givethe participants the opportunity to get together. Mini-tabs for MP formulations – challenges, oppor-tunities and trendsJan LüdemannNordmark Arzneimittel GmbH & Co. KG, Germany CR pellets by melt extrusion – formulation and applicationsBrigitte SkalskyEvonik Industries AG, Pharma Polymers, Germany Industrial case study – MP formulation from lab toproductionGuido RadtkeBoehringer Ingelheim Pharma GmbH & Co. KG, Germany Industrial case study – MP tablets: Reminyl controlledrelease multiparticulatesGeert VerreckJanssen R&D a division of Janssen Pharmaceutica N.V., Belgium Wednesday, 14th November 2012 9:00 to 16:00 h • Innovative and advanced MP formulations, using PAT in particle coating Ingela Niklasson-Björn • Practical aspects of manufacturing and scale up for AstraZeneca AB R&D Mölndal, Sweden (not yet confirmed) In-vitro dissolution testing of multiparticulate systems • Up to date information on QbD and PAT aspects for Sandra KleinErnst-Moritz-Arndt-University Greifswald, Germany • Formulation considerations for the treatment of Taste masking of multiparticulatesJörg Breitkreutz Heinrich-Heine-University Düsseldorf, Germany • Table top exhibition on latest innovation in equip- Case studies IVIVC aspects of MP drug delivery systemsSandra KleinErnst-Moritz-Arndt-University Greifswald, Germany This will be an excellent opportunity for those new tothe use of multiparticulates as well as those who are Session 5: Pediactric and geriatric treatment familiar and experienced in this area. Attendees willbe able to apply their learning from this workshop to Multiparticulates – the solution for children? Jörg BreitkreutzUCL School of Pharmacy, United Kingdom You are kindly invited to submit abstracts for poster presentations during the conference. Detailed infor- mation for authors and submission are available onli-ne on the website: www.apv-mainz.de Deadline for abstract submisssion: 15th October 2012 As an exhibitor you will be also invited to attend thesessions and network at the Get Together Dinner inthe evening that is part of the conference program-me. Price for a table top space with table, chairs andpower supply is 990 EUR plus one mandatory full con-ference registration.
Please contact the APV headquarters Phone +49 6131 9769-85 e-mail sp@apv-mainz.de By postal service to:APV Arbeitsgemeinschaft fürPharmazeutische Verfahrenstechnik e.V.
Kurfürstenstraße 59D-55118 Mainz Course No. 6469Oral Multiparticulate Dosage Forms – What's new? from 13th to 14th November 2012

Source: http://apv2011-2.kundenfenster.de/fileadmin/Pdf_Programme_2012/6469_Pharma_Seminare_Multiparticulate.pdf